Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
批准号:
10589801
负责人:
OFER LEVY
金额:
$11.18万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-10 至 2027-02-28
关键词:
AdherenceAsthmaCellsChildhoodClinicalCommunicable DiseasesCommunicationComplementDataDevelopmentDissectionEnsureEpigenetic ProcessFundingGeographyGoalsHumanImmuneImmune responseImmunologyIn VitroInfantInfrastructureIntellectual PropertyInternationalLeadershipLifeMediatingMolecularOutcomePRTN3 genePredispositionProcessProductivityProgress ReportsProperty RightsProteomicsRecommendationResearch PersonnelResearch Project GrantsShapesStructureSystems BiologyTechnologyTeleconferencesUnited States National Institutes of HealthVaccinesWorkconflict resolutiondata managementdesignimprovedin silicointer-institutionalmaterial transfer agreementmeetingsprogramsrespiratorysymposiumsynergismtimelinetranscriptomicsvaccine responsevaccinology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY: IDEAL Administrative Core
Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes
that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious
disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow
complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3)
research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the
study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed
studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute
streamlined processes which facilitate productive interactions among investigators from each IDEAL Project
and Core. We will achieve this goal by pursuing the following Specific Aims (SAs):
SA1. Provide infrastructure for administrative leadership aimed at building an interactive and
collaborative working team resulting in maximal project synergy.
SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads
by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as
seminars/symposia focused on the IDEAL project.
SA3. Manage and optimize communication within our IDEAL team and between our team, the
other NIH supported IDEAL teams and the IDEAL Steering Committee.
SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by
implementing recommendations of the Conflicts Resolution Group (CRG).
SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress
reports sent to the NIH.
SA6. Protect intellectual property rights of our investigators and execute material transfer
agreements.
SA7. Implement the data management/sharing plan among investigators within and outside of our
IDEAL team.
Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to
project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
-
批准号:10435035
-
项目类别:
-
资助金额:$166.59万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
-
批准号:10589826
-
项目类别:
-
资助金额:$22.79万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
-
批准号:10435043
-
项目类别:
-
资助金额:$19.86万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
-
批准号:10589800
-
项目类别:
-
资助金额:$154.65万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
-
批准号:10435036
-
项目类别:
-
资助金额:$12.39万
-
财政年份:2022
-
负责人:OFER LEVY
-
依托单位:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
-
批准号:10290547
-
项目类别:
-
资助金额:$212.99万
-
财政年份:2021
-
负责人:OFER LEVY
-
依托单位:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
-
批准号:10205742
-
项目类别:
-
资助金额:$80.05万
-
财政年份:2021
-
负责人:OFER LEVY
-
依托单位:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
-
批准号:10323182
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10221106
-
项目类别:
-
资助金额:$11.11万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265669
-
项目类别:
-
资助金额:$210.3万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses
-
批准号:10323193
-
项目类别:
-
资助金额:$85.52万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Clinical and Data Coordinating Center (CDCC)]
-
批准号:10323176
-
项目类别:
-
资助金额:$210.3万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265671
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265673
-
项目类别:
-
资助金额:$85.52万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
-
批准号:10265672
-
项目类别:
-
资助金额:$227.57万
-
财政年份:2020
-
负责人:OFER LEVY
-
依托单位:
Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines
-
批准号:10473587
-
项目类别:
-
资助金额:$25.7万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Small-molecule adjuvants testing pipeline (Influenza)
-
批准号:10834716
-
项目类别:
-
资助金额:$139.21万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly
-
批准号:10027076
-
项目类别:
-
资助金额:$172.29万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines
-
批准号:10301484
-
项目类别:
-
资助金额:$179.03万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
Small-molecule adjuvants testing pipeline (Influenza)
-
批准号:10641647
-
项目类别:
-
资助金额:$212.73万
-
财政年份:2019
-
负责人:OFER LEVY
-
依托单位:
海外基金